The Three Reasons Sponsors Choose Australia

It starts faster

Getting a clinical trial off the ground involves submitting a package of documents to an ethics committee for review. In the US and UK, that package is substantial. In Australia, the minimum requirement for a first-in-human study is three documents: your study protocol, an informed consent form (which the trial site can often help you write), and an investigator brochure summarizing what you know about the drug so far.

“All you need is your protocol, your informed consent, which your site can write for you, and your investigator brochure. That’s it. That’s all that’s needed.”

Fewer documents means you can submit earlier. Earlier submission means the trial starts earlier. Most Australian phase I trials reach start-up within six to eight weeks. The science and safety review is just as rigorous; there is simply less paperwork standing between you and it.

The data is accepted everywhere

A common concern for founders considering an unfamiliar jurisdiction is whether regulators in their home market will accept the data. For Australia, the answer is yes.

Australian trial sites operate under the same international standards as the US and EU. Labs are independently accredited and audited. The FDA and EMA both accept data generated in Australian trials. If you plan to run later-stage trials in the US or Europe, the data from your Australian phase I will travel with you.

Australia is ranked third globally for the total number of first-in-human trials, which means Australian investigators and sites have deep, concentrated experience in this specific kind of work. That expertise matters when something unexpected happens, as it often does in early trials.

It costs less, with a meaningful tax refund on top

Running a trial in Australia is less expensive than the US or UK for two reasons. First, the Australian dollar exchange rate is generally favorable for sponsors spending in US dollars or euros. Second, Australia offers an R&D Tax Incentive that provides a cash refund of up to approximately 48.5% on eligible research spending for smaller companies.

That last point is worth pausing on. For a company that qualifies, nearly half of its Australian trial expenditure can come back as cash. The incentive requires careful structuring, particularly around how your company is set up and how contracts are written, but the economics are real and material.

What Makes It Work Operationally

Australia’s clinical trial ecosystem is small and well-connected. The major trial activity is concentrated in five capital cities, which means the contract research organizations, trial sites, labs, and regulatory advisors all know each other and work together regularly.

For a founder running a trial from North America or Europe, that density is an advantage. You are not coordinating between strangers across a fragmented network. You are working with a system that already functions as a unit.

“That network is one of the key advantages of the Australian ecosystem.”

What Kinds of Trials Run There

Australia has active trial programs across most major therapeutic areas. Metabolic disease (including the wave of GLP-1 and obesity drugs), autoimmune conditions, oncology, and vaccine development are all well-represented. Cell and gene therapies, including CAR-T, are a growing area.

One specific advantage for vaccine developers: Australia’s seasons are reversed relative to the Northern Hemisphere. That gives sponsors access to winter respiratory infection seasons at times when the US and Europe are in summer, which can matter for certain trial designs.

Things to Know Before You Start

The regulatory body works differently. In Australia, the ethics committee (called the HREC) is the primary reviewer of your trial. The national medicines regulator, the TGA, is notified but does not conduct a separate approval review for most early-phase studies. This is different from the FDA or EMA process and is part of why start-up is faster.

Some products need additional clearance. If your therapy involves a biological or is classified as a GMO under Australian law, you may need approvals beyond the standard ethics process. This varies by product. Check early.

Trial registration is required. Australia requires clinical trials to be registered in a public database before they begin. Some other jurisdictions allow delays for early-phase studies. Factor this into your timeline.

Tax structuring matters. To access the R&D Tax Incentive, your Australian entity must directly incur the trial expenditure and have appropriate access to the intellectual property being developed. How you structure contracts and licensing arrangements before you start will affect what you can claim. Get advice before you sign anything.

The Short Version

Australia is the third-largest destination globally for first-in-human trials. It starts faster, costs less, produces globally accepted data, and operates through a tight, experienced ecosystem. The reasons most international founders have not considered it are informational, not substantive.

“When we look at the three main reasons why international sponsors consider Australia for their clinical studies, it’s predominantly around speed, quality and cost.”

If you are approaching your first human trial and have not looked at Australia, it is worth adding to the conversation.